Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1):61-7

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1):61-7

NEUROENDOCRINE UPDATE AND METABOLIC THERAPY 

    ORIGINAL ARTICLES

Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions

Prasad V., Baum R. P.

Department of Nuclear Medicine/Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany

AIM: The aim of the study was 1) to determine the normal biodistribution of radiolabeled somatostatin analogue 68Ga DOTA-NOC; 2) to establish the range of its uptake in liver, bone and lymph node metastases in patients with NET, 3) to establish the cut-off value for differentiating between physiological uptake and tumor related sstr expression in the processus uncinatus of pancreas.
METHODS: Maximum standardized uptake values (SUVmax) of 68Ga DOTA-NOC were determined in normal organs of 89 NET patients undergoing receptor PET/CT. In addition, SUVmax of primary pancreatic neuroendocrine tumors (pNET), liver, bone and lymph node metastases were evaluated.
RESULTS: SUVmax (mean±standard deviation) were determined in: pituitary gland 2.6±1.3, thyroid: 3.4±1.4, lung: 0.9±0.8, normal liver: 6.9±2 , spleen: 22.0±10.0, adrenal 6.0±2.5, kidney: 12.9±3.8, gastrointestinal tract 2.3±1.0, gluteal muscle:1.0±0.3, femur 0.8±0.3, blood pool 2.6± 1.2 and processus uncinatus of pancreas 5.8±2.0. SUVmax of 68Ga DOTA-NOC was 19.6±13.4 (N.=200) in liver metastases, 12.5±10 (N.=67) in lymph nodes metastasis, 9.5±6.0 (N.=78) in bone lesions, and 20.8±10.8 (N.=26) in pancreatic neuroendocrine primary tumors. Target to non target (T/NT) ratios were 3.4±2.3 for liver metastases (with normal CONCLUSIONS: There is a broad range of sstr expression in metastastic lesions and in pNET. The splenic uptake of 68Ga DOTA-NOC is highly variable. 68Ga DOTA-NOC is an excellent tracer for imaging somatostatin receptor positive tumors, which, due to the high target to non-target ratios, allows the detection of very small lesions, especially of lymph node and bone metastases.

language: English


FULL TEXT  REPRINTS

top of page